^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Adcetris (brentuximab vedotin)

    i
    Other names: cAC10-vcMMAE, SGN 35, SGN-35, SGN-035, SGN35, SGN 035, SGN035
    Company:
    Pfizer, Takeda
    Drug class:
    Microtubule inhibitor, CD30-targeted antibody-drug conjugate
    Related drugs:
    Apply
    Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL (ACCELERATE) (NCT07013565)
    Phase 2
    New York Medical College
    Not yet recruiting
    Last update posted :
    06/10/2025
    Initiation :
    07/01/2025
    Primary completion :
    07/01/2029
    Completion :
    07/01/2030
    PD-L1
    |
    Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • vinblastine
    Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (P30CA033572) (NCT03113500)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/25/2017
    Primary completion :
    07/16/2021
    Completion :
    08/12/2025
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous
    A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) (NCT02588651)
    Phase 2
    Deepa Jagadeesh
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    06/17/2016
    Primary completion :
    10/14/2024
    Completion :
    10/14/2024
    TNFRSF8
    |
    Adcetris (brentuximab vedotin)
    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery (NCT03007030)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    04/05/2017
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    TNFRSF8
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (LCCC1637) (NCT03264131)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/11/2018
    Primary completion :
    12/15/2023
    Completion :
    12/15/2028
    TNFRSF8
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous
    Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides (NCI-2022-03831) (NCT05357794)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/13/2022
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    TNFRSF8 • CD4
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (NCT03755804)
    Phase 2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    12/12/2018
    Primary completion :
    01/01/2027
    Completion :
    07/01/2028
    TNFRSF8
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • cyclophosphamide intravenous • Neupogen (filgrastim) • prednisolone
    Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (KEYNOTE B81) (NCT04609566)
    Phase 2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    01/26/2021
    Primary completion :
    12/31/2025
    Completion :
    09/30/2026
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • BRAF mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)
    Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (E4412) (NCT01896999)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/07/2014
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PD-1 • CD4 • LGALS1 • ICOS
    |
    TNFRSF8 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression (SGN35-032) (NCT04569032)
    Phase 2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/12/2020
    Primary completion :
    05/09/2024
    Completion :
    12/31/2025
    TNFRSF8
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous
    SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) (NCT01352520)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/01/2011
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    TNFRSF8
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)